Stocktoria
Jiangsu Hengrui Pharmaceuticals Co.,Ltd 600276.SS
CN · Shanghai Stock Exchange · XSHG · stock · Healthcare · website
Jiangsu Hengrui Pharmaceuticals Co.,Ltd financials (annual, from 10-K)
Bars are annual figures from 2022 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $31.6B | $28.0B | $22.8B | $21.3B |
| Gross profit | $27.3B | $24.1B | $19.3B | $17.8B |
| R&D expense | $7.0B | $6.6B | $5.0B | $4.9B |
| SG&A expense | $7.4B | $7.2B | $6.5B | $6.2B |
| Operating income | $8.6B | $6.8B | $4.6B | $3.3B |
| Interest expense | $14.3M | $5.6M | $5.9M | $6.5M |
| Income tax | $990.6M | $832.7M | $389.3M | $153.4M |
| Net income | $7.7B | $6.3B | $4.3B | $3.9B |
| EPS (diluted) | $1.18 | $1.00 | $0.68 | $0.61 |
| Operating cash flow | $11.2B | $7.4B | $7.6B | $1.3B |
| Free cash flow | $8.3B | $5.5B | $6.2B | -$726.9M |
| Cash & equivalents | $41.0B | $24.8B | $20.7B | $15.1B |
| Inventory | $2.9B | $2.4B | $2.3B | $2.5B |
| Total assets | $69.9B | $50.1B | $43.8B | $42.4B |
| Total liabilities | $8.1B | $4.0B | $2.8B | $4.0B |
| Shareholders' equity | $61.3B | $45.5B | $40.5B | $37.8B |
Growth · year-over-year · Revenue CAGR 14.1%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue growth | +13.0% | +22.6% | +7.3% | — |
| Net income growth | +21.7% | +47.3% | +10.1% | — |
| EPS growth | +18.0% | +47.1% | +11.5% | — |
| Free cash flow growth | +51.7% | -11.5% | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Source: company filings via Yahoo Finance · CN · as of 2025-12-31. Figures in CNY; non-US fundamentals are aggregated by Yahoo (shorter history); facts plus Stocktoria's own computed scores — not investment advice.